R Squared Ltd Buys Shares of 52,459 Sangamo Therapeutics, Inc. $SGMO

R Squared Ltd purchased a new stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 52,459 shares of the biopharmaceutical company’s stock, valued at approximately $28,000.

A number of other hedge funds also recently made changes to their positions in SGMO. Jacobs Levy Equity Management Inc. boosted its position in Sangamo Therapeutics by 74.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company’s stock worth $851,000 after buying an additional 555,323 shares during the period. GSA Capital Partners LLP boosted its position in Sangamo Therapeutics by 2,962.2% during the 1st quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock worth $634,000 after buying an additional 934,649 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Sangamo Therapeutics during the 1st quarter worth approximately $47,000. Invesco Ltd. boosted its position in Sangamo Therapeutics by 82.8% during the 1st quarter. Invesco Ltd. now owns 483,894 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 219,253 shares during the period. Finally, Meritage Portfolio Management boosted its position in Sangamo Therapeutics by 37.3% during the 2nd quarter. Meritage Portfolio Management now owns 127,000 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 34,500 shares during the period. 56.92% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Stock Down 3.6%

NASDAQ:SGMO opened at $0.63 on Monday. The company has a fifty day moving average of $0.60 and a 200-day moving average of $0.58. The firm has a market capitalization of $191.07 million, a P/E ratio of -2.18 and a beta of 1.22. Sangamo Therapeutics, Inc. has a twelve month low of $0.41 and a twelve month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $18.31 million for the quarter, compared to the consensus estimate of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. On average, analysts anticipate that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, September 4th. Wall Street Zen upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sangamo Therapeutics in a research report on Saturday. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $4.50.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.